todays the day !!!, page-76

Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol 'UNIS' Unilife CEO to Ring NA

Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol 'UNIS' Unilife
CEO to Ring NASDAQ Closing Bell on February 22, 2010

Tue Feb 16 10:12:00 2010
EST
LEWISBERRY, Pa., Feb 16, 2010 /PRNewswire via COMTEX News Network/ --
Unilife Corporation (Company) (Nasdaq: UNIS, ASX: UNS) today announced that
the Company's common stock began trading on the NASDAQ Global Market on Tuesday,
February 16, 2010, under the ticker symbol "UNIS."
"This is a major step for Unilife Corporation, signifying the completion
of its transition from the Australian Stock Exchange into a publicly listed U.S.
company. I believe moving the Company to the U.S. and listing our common stock
on a major international exchange complements our rapid emergence as a global leader
for innovative safety medical devices," stated Alan Shortall, CEO of Unilife.
Investors wishing to trade on either the NASDAQ or ASX are invited to visit
the Company's website (www.unilife.com) to access information on Unilife Corporation,
including a list of Frequently Asked Questions. The Company has also opened an Investor
Hotline to assist with shareholder inquiries. The inquiry hotline numbers are 1-800-632-680
(Australia toll free), +1-866-496-5819 (US toll free) and or +61 2 8256 3394 (International).
Unilife is also pleased to advise that CEO Alan Shortall will preside over
the NASDAQ closing bell ceremony on Monday, February 22, 2010. Members of Unilife's
management team and guests will join Mr. Shortall at the ceremony, which will take
place at the NASDAQ MarketSite in Times Square and will be broadcast live.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the
design, development, manufacture and supply of a proprietary range of retractable
syringes. Primary target customers for Unilife products include pharmaceutical manufacturers,
suppliers of medical equipment to healthcare facilities and patients who self-administer
prescription medication. These patent-protected syringes incorporate automatic and
fully-integrated safety features which are designed to protect those at risk of
needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified
and has FDA-registered medical device manufacturing facilities in Pennsylvania.
Unilife's main product is the Unifill(TM) ready-to-fill syringe, which is
designed to be supplied to pharmaceutical manufacturers in a form that is ready
for filling with injectable drugs and vaccines. Unilife has a strategic partnership
with sanofi-aventis, a large global pharmaceutical company, pursuant to which it
has paid Unilife a euro 10 million exclusivity fee and has committed to pay up to
an additional euro 17 million to fund an industrialization program for the Unifill(TM)
syringe. Upon the scheduled completion of the industrialization program in late
2010, Unilife expects to commence the supply and sale of the Unifill(TM) syringe
to sanofi-aventis. Unilife is also in discussions with other pharmaceutical companies
that are seeking to obtain access to the Unifill(TM) syringe.
This press release contains forward-looking statements. All statements that
address operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements. These forward-looking statements
are based on management's beliefs and assumptions and on information currently available
to our management. Our management believes that these forward-looking statements
are reasonable as and when made. However, you should not place undue reliance on
any such forward-looking statements because such statements speak only as of the
date when made. We do not undertake any obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by law. In addition, forward-looking statements
are subject to certain risks and uncertainties that could cause actual results,
events and developments to differ materially from our historical experience and
our present expectations or projections. These risks and uncertainties include,
but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere
in our registration statement on Form 10 and those described from time to time in
our future reports which we will file with the Securities and Exchange Commission.



Investor Contacts (US):
Todd Fromer / Garth Russell Stuart Fine
KCSA Strategic Communications Carpe DM Inc
Phone + 1 212-682-6300 Phone + 1 908 469 1788

Investor Contacts (Australia)
Jeff Carter
Unilife Corporation
Phone + 61 2 8346 6500


SOURCE Unilife CorporationCopyright (C) 2010 PR Newswire. All rights reserved

UNIS,

PA-UnilifeCorp-NASDAQ, ASIA_PACIFIC, BUSINESS, csta+stories, FINANCE, financenews, financenews+select,
GLOBAL+NEWS, HEALTHCARE, hedge+funds, INTERNATIONAL, PHARMACEUTICALS, prn, PUBCO+SELECT, PUBLIC+COMPANIES,
WALL+STREET,

This content is for use with eSignal products by authorized persons only. Any reference; link, frame,
or other use of this material without the explicit permission of eSignal is prohibited.